School of Pharmacy, University of Otago, Dunedin, New Zealand; Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark.
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):873-81. doi: 10.1016/j.ejpb.2013.03.014. Epub 2013 Mar 26.
Poor aqueous solubility of an active pharmaceutical ingredient (API) is one of the most pressing problems in pharmaceutical research and development because up to 90% of new API candidates under development are poorly water soluble. These drugs usually have a low and variable oral bioavailability, and therefore an unsatisfactory therapeutic effect. One of the most promising approaches to increase dissolution rate and solubility of these drugs is the conversion of a crystalline form of the drug into its respective amorphous form, usually by incorporation into hydrophilic polymers, forming glass solutions. However, this strategy only led to a small number of marketed products usually because of inadequate physical stability of the drug (crystallization). In this study, we investigated a fundamentally different approach to stabilize the amorphous form of drugs, namely the use of amino acids as small molecular weight excipients that form specific molecular interactions with the drug resulting in co-amorphous forms. The two poorly water soluble drugs carbamazepine and indomethacin were combined with amino acids from the binding sites of the biological receptors of these drugs. Mixtures of drug and the amino acids arginine, phenylalanine, tryptophan and tyrosine were prepared by vibrational ball milling. Solid-state characterization with X-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC) revealed that the various blends could be prepared as homogeneous, single phase co-amorphous formulations indicated by the appearance of an amorphous halo in the XRPD diffractograms and a single glass transition temperature (Tg) in the DSC measurements. In addition, the Tgs of the co-amorphous mixtures were significantly increased over those of the individual drugs. The drugs remained chemically stable during the milling process and the co-amorphous formulations were generally physically stable over at least 6 months at 40 °C under dry conditions. The dissolution rate of all co-amorphous drug-amino acid mixtures was significantly increased over that of the respective crystalline and amorphous pure drugs. Amino acids thus appear as promising excipients to solve challenges connected with the stability and dissolution of amorphous drugs.
活性药物成分(API)的水溶性差是药物研发中最紧迫的问题之一,因为高达 90%的新开发 API 候选物水溶性差。这些药物通常口服生物利用度低且可变,因此治疗效果不理想。提高这些药物的溶解速率和溶解度的最有前途的方法之一是将药物的结晶形式转化为其相应的无定形形式,通常是通过掺入亲水性聚合物中,形成玻璃溶液。然而,这种策略仅导致少数上市产品,通常是因为药物(结晶)的物理稳定性不足。在这项研究中,我们研究了一种从根本上不同的方法来稳定药物的无定形形式,即使用氨基酸作为小分子赋形剂,与药物形成特定的分子相互作用,从而形成共无定形形式。两种水溶性差的药物卡马西平和吲哚美辛与这些药物的生物受体结合部位的氨基酸结合。通过振动球磨制备药物与精氨酸、苯丙氨酸、色氨酸和酪氨酸氨基酸的混合物。X 射线粉末衍射(XRPD)和差示扫描量热法(DSC)的固态表征表明,各种混合物可以作为均相、单相共无定形制剂制备,这表明 XRPD 衍射图谱中出现无定形晕和 DSC 测量中的单个玻璃化转变温度(Tg)。此外,共无定形混合物的 Tg 明显高于单独药物的 Tg。在研磨过程中,药物保持化学稳定,共无定形制剂在至少 6 个月的时间内在 40°C 干燥条件下通常具有物理稳定性。所有共无定形药物-氨基酸混合物的溶解速率均明显高于各自的结晶和无定形纯药物。因此,氨基酸似乎是解决无定形药物稳定性和溶解问题的有前途的赋形剂。